News: Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,713JPY
25 Dec 2014
Price Change (% chg)

-- (--)
Prev Close
¥1,713
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
8,664,220
52-wk High
¥1,842
52-wk Low
¥1,062

Search Stocks
Select another date:

Mon, Dec 1 2014

BRIEF-Astellas announces end of license agreement with Janssen Biotech

* Announces end of license agreement with janssen biotech to develop oral janus kinase inhibitor

CORRECTED-UPDATE 2-Dendreon files for bankruptcy as cancer vaccine disappoints

(Corrects paragraph 6 to say Xtandi is marketed by Medivation and Astellas)

REFILE-TABLE-Astellas -6-MTH group results (IFRS)

(Operating forecast is core operating forecast, EPS forecast is core EPS forecast.Adds core net profit) Oct 31 - Astellas Pharma Inc. CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) 6 months ended 6 months ended Year to Sep 30, 2014 Sep 30, 2013 Mar 31, 2015 LATEST YEAR-AGO COMPANY RESULTS

U.S. FDA approves expanded use of Medivation prostate cancer drug

- U.S. health regulators approved the use of Medivation Inc's and Astellas Pharma Inc's advanced prostate cancer drug Xtandi in men who have not yet received chemotherapy, the companies said on Wednesday, significantly expanding the potential patient population for the oral medicine.

UPDATE 1-U.S. FDA approves expanded use of Medivation prostate cancer drug

Sept 10 - U.S. health regulators approved the use of Medivation Inc's and Astellas Pharma Inc's advanced prostate cancer drug Xtandi in men who have not yet received chemotherapy, the companies said on Wednesday, significantly expanding the potential patient population for the oral medicine.

Select another date:
Search Stocks